 CULVER CITY, Calif.--BUSINESS WIRE--ImmunityBio, Inc. NASDAQ: IBRX, a clinical-stage immunotherapy company, today reported initial data indicating that a single subcutaneous injection of the companys COVID-19 vaccine candidate in healthy Phase 1 clinical study participants stimulates the generation of T cells that are reactive to the spike S and nucleocapsid N protein antigens delivered by the vaccine. Just 14-16 days after the single dose, the mean level of T cells generated in respon 